{
    "address": "Skeppsbron 2, 1 TR",
    "city": "Malmo",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W34064191",
    "description": "Gabather AB engages in the research and development of drug candidates for treatment of diseases affecting the central nervous system. The company is headquartered in Malmo, Skane. The company went IPO on 2014-11-03. The firm develops drug candidates for the treatment of several diseases originating in the central nervous system (CNS). The firm mainly focuses on anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as conginition-enhancing treatments, including Alzheimer\u2019s disease.",
    "employeeTotal": "",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Pharmaceuticals",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Pharmaceuticals",
    "gsector": "Health Care",
    "gsubind": "Pharmaceuticals",
    "ipo": "2014-11-03",
    "isin": "SE0010869552",
    "logo": "",
    "marketCapitalization": 80.95576,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in Biotechnology",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Gabather AB",
    "phone": "",
    "sedol": "BYVSFM7",
    "shareOutstanding": 13.403272,
    "state": "SKANE",
    "ticker": "GABA.ST",
    "weburl": ""
}